Shelley Chu, a former executive at Gilead Sciences Inc, has joined Abingworth as a partner working at the investment group’s offices in Menlo Park, California, US. Dr Chu led business development at Gilead, overseeing products in the fields of oncology, immunotherapy and hepatitis B. Prior to that she was a principal at Frazier Healthcare Ventures and earlier, an investment professional at Flagship Ventures. She holds a doctorate of medicine and a PhD in biochemistry and biophysics from the University of California, San Francisco.
Abingworth announced the appointment on 19 October 2015.
Copyright 2013 Evernow Publishing Ltd